

Depression on Dialysis

Joseph Chilcot^{a, b} David Wellsted^b Maria Da Silva-Gane^a Ken Farrington^{a, b}

^aRenal Unit, Lister Hospital, Stevenage, and ^bUniversity of Hertfordshire, Hatfield, UK

Key Words

Depression · End-stage renal disease · Dialysis · Beck depression inventory · Criterion contamination

Abstract

Depression is the most common psychopathological condition among patients with end-stage renal disease (ESRD), yet it is still under-recognized and misdiagnosed. Depression reduces quality of life and has a negative clinical impact upon sufferers with chronic illness, including ESRD. This article discusses the negative effects of depression among the ESRD population treated with dialysis, the prevalence of the condition, the methodological issues involved with screening and treatment, and the possible psychological and somatic causes. There is a need to identify the prevalence of the disorder by effective methods, overcome the current issues surrounding depression assessment and to undertake trials of suitable treatments.

Copyright © 2008 S. Karger AG, Basel

Introduction

End-stage renal disease (ESRD) has a significant impact upon the lives of sufferers. The experience of multiple losses, including kidney function, family role, work role, sexual function, time and mobility, impact significantly on the lives of patients [1, 2]. Further stressors, including medication effects [3], dietary constraints, fear of

death and dependency upon treatment [4–7], may affect quality of life and exacerbate feelings of a loss of control. It has been widely claimed that depression is the most common psychopathological condition among patients with ESRD [2, 3, 8, 9]. While prevalent, depression is still often unrecognized [10], reflecting a lack of routine psychological evaluation among this patient population [11]. The consequences of missing depression among dialysis patients may be considerable. Comorbid depressive illnesses amplify the impact of chronic illnesses, and increase functional disability and the use of health care services [12]. This article discusses the prevalence, the issues surrounding screening and treatment, and the possible causes and consequences of depression in the dialysis population.

Assessing Depression among Chronically Ill Populations: The Issue of Criterion Contamination

Major depressive disorder is defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), as having a loss of pleasure or interest for 2 weeks, accompanied by 5 or more psychological, somatic and behavioural symptoms. Sadness, emotional inhibitions, lack of energy, sleep disturbances, loss of concentration, intense guilt, and thoughts of suicide or death are some of the symptoms associated with major depression. Thoughts of suicide and death are particular symptoms that are of obvious concern.

KARGER

Fax +41 61 306 12 34
 E-Mail karger@karger.ch
www.karger.com

© 2008 S. Karger AG, Basel
 1660–2110/08/1084–0256\$24.50/0

Accessible online at:
www.karger.com/nec

Joseph Chilcot
 Renal Unit Lister Hospital
 Coreys Mill Lane
 Stevenage SG1 4AB (UK)
 Tel./Fax +44 143 878 1340, E-Mail josephchilcot@nhs.net

Depression assessment can involve screening or diagnostic assessment. Diagnosis can be undertaken using a diagnostic criterion such as DSM-IV or the International Classification of Diseases (ICD-10). Trained professionals conduct diagnostic assessments typically via structured or semi-structured interviews. Depression screening tools are usually self-reports, requiring the patient to rate symptom frequency or severity. Screening tools employ cut-offs, which are used to indicate depression or significant depressive symptomatology, typically classifying patients by symptom severity (mild, moderate or severe). While screening tools are easier to administer, with several validated against diagnostic criteria, they cannot be used to diagnose clinical depression (major depressive disorder) or other depressive disorders. Whether employed in research or clinical practice, depression assessments differ technically with regard to their diagnostic potential, and different screening tools have varied sensitivities and specificities across different populations.

When applied to chronically ill populations, both screening tools and diagnostic schemes are sensitive to criterion contamination, in that they include somatic enquiry, which overlaps with the symptomatology of physical illness. With regard to ESRD, the somatic ramifications of uraemia, including fatigue, sleep disorders and reduced appetite, are also somatic indicators of depression [13]. A patient with significant uraemic symptoms will score highly on these elements. Consequently researchers and clinicians are left in a predicament about whether these somatic symptoms are the result of depression, illness or a combination of both. The issue of criterion contamination is not unique to ESRD, and impacts upon a range of conditions [14]. It is probable that criterion contamination interferes with depression screening in most, if not all, medical illnesses to varying degrees. Between 50 and 80% of medical inpatients report somatic complaints, including psychomotor retardation, fatigue, anorexia, weight loss and insomnia [15, 16]. Whether these overlapping symptoms should be removed, substituted or included in the diagnostic scheme remains open to debate [17]. Contamination is also encountered in the evaluation of less severe psychological symptoms. Cavanaugh et al. [18] found that one third of non-depressed medically ill patients reported significantly more irritability, sadness, crying, mild pessimism, indecisiveness and dissatisfaction compared to healthy individuals. These milder symptoms have been attributed to an emotional response to the stress of illness and hospitalization [16]. The severer cognitive symptoms including depressed

mood, guilt, loss of interest and concentration difficulties have been associated with major depressive disorder (DSM-III-R) in the ESRD population [19]; thus, they may be suitable discriminators for the disorder in this population.

In an attempt to reduce the influence of somatic factors in the assessment of depression, the Cognitive Depression Index (CDI) [20], a subscale of the Beck Depression Inventory (BDI) with somatic questions excluded, has been employed. Sacks et al. [20] suggest that the CDI might be a better predictor of depression due to the reduction of confounding symptoms. However, there is little evidence that the cognitive and somatic elements of depression can be separated using the CDI [1, 3, 21]. Drayer et al. [22] found that depressed dialysis patients report more somatic symptoms than non-depressed ones, and that physical symptoms relate more closely to depression than medical comorbidity [23]. In our pilot study of haemodialysis (HD) patients, we found that the BDI (including somatic enquiry, using a cut-off ≥ 16) had greater sensitivity (88.9%) and specificity (87.1%) as compared to a diagnostic interview, than the CDI (excluding somatic enquiry, cut-off ≥ 10 , sensitivity 77.8% and specificity 80.6%) [24].

In addition to determining the most effective depression screening tool, the procedure for screening also requires attention, which our recent study goes some way to addressing. We found that administering the BDI to dialysis patients while they received their treatment agreed highly with off-dialysis assessments [24]. Interestingly, on-dialysis assessments lead to slightly increased somatic scoring; thus, they may reduce false-negative cases, albeit via increased false-positives. When screening a population, it is certainly more favourable to have a tool that reduces false-negatives as opposed to increasing them. Evidence from our research suggests that on-dialysis BDI assessments are a practical method for screening HD patients, improving the detection and monitoring of depression symptoms.

The Prevalence of Depression among the Dialysis Population

It is estimated that depression is the second most common condition encountered in general practice (World Health Organization), with the lifetime prevalence reported to be 16.2% [25]. Among the medically ill, depression is a common concern accounting for half of the identified psychopathology [26].

Table 1. Prevalence of depression among renal dialysis patients, employing screening or diagnostic schemes

Study	Measure/cut-off	Population	Prevalence %	95% confidence interval, %	n
Lowry and Atcherson [27]	American Psychiatric Association criteria	Initiating home HD	18	11.1–27.8	83
Smith et al. [28]	BDI Multiple Affect Adjective Check List DSM-III	HD, PD	47	34.7–59.7	60
			17	9.4–28.7	
			5	1.7–13.9	
Wuerth et al. [29]	BDI ≥ 11	PD	49	44–54	380
Wilson et al. [30]	BDI ≥ 14 Nurse Nephrology team	HD	38.7	30.5–47.6	124
			41.9	33.5–50.8	
			24.2	17.5–32.5	
Sacks et al. [20]	BDI ≥ 16	HD, PD	26	16.2–38.9	57
Kimmel [1]	BDI > 15 BDI > 10	HD	24.7	20.1–29.9	300
			46.4	40.8–52.1	
Lopes et al. [31]	CES-D ≥ 10 Physician diagnosed	HD	43.0	41.8–44.2	6,987
			13.9	13.1–14.7	
Craven et al. [19]	Diagnostic Interview Schedule III	HD, PD	8.1	4.1–15.3	99
Martin et al. [32]	HADS ≥ 8	HD	71.4	52.1–85.2	28
		PD	25	16.3–36.3	72
Boulware et al. [33]	MHI-5 ≤ 52 (baseline) MHI-5 ≤ 52 (over time)	HD, PD	19	16.6–21.7	917
			24	21.3–26.9	
Lopes et al. [34]	Physician diagnosed 'Down hearted and blue question' ¹ 'So down in the dumps ...' ¹	HD	17.7	16.5–18.6	5,256
			21.5	20.4–22.7	4,881
			19.5	18.4–20.6	4,901
Drayer et al. [22]	Primary Care Evaluation of Mental Disorders	HD	28	18.2–40.5	62
Hinrichsen et al. [35]	Research diagnostic criteria – minor/major depressive disorder	HD	17.7	11.9–25.4	124
			6.5	3.3–12.3	
Hedayati et al. [36]	Structured Clinical Interview DSM-IV	HD	26.5	18.7–36.1	98
Kalender et al. [37]	Structured Clinical Interview DSM-IV	HD	33.8	23.5–45.9	68
		PD	12.8	5.9–25.6	47
Watnick et al. [10]	Structured Clinical Interview DSM-IV	HD, PD	19	11.0–30.7	62

MHI-5 = Subscale of Medical Outcomes Study Short Form 36; CES-D = Centre for Epidemiological Studies Depression Screening Index.

¹ Unconventional approach – questions taken from the Kidney Disease and Quality of Life Short Form.

It has been suggested that approximately 20–30% of the ESRD population suffer from depression [1, 8, 22, 38], although research has tended to focus on the HD population and neglected patients receiving peritoneal dialysis (PD). The exact prevalence remains contentious, as evidenced by the wide variations reported in the ESRD literature (table 1). Indeed, there is much variation regarding the prevalence of depression among medically ill pa-

tients, ranging from 15 to 61% [39]. A recent investigation reported that 38.8% of HD patients screened using the BDI scored ≥ 14 [30]. A similar prevalence was reported by Martin et al. [32] after screening dialysis patients with the Hospital Anxiety Depression Rating Scale (HADS). Defining depression as 'a HADS depression score of ≥ 8 ' led to 34.4% of patients meeting this criterion. However, when using a more stringent score (HADS depression

score ≥ 11), the prevalence was reduced to only 6.3% [32].

The variation in reported prevalence changes with the type of assessment undertaken and is dependent upon which depression definition is used. Depression screening tools often reveal a higher prevalence compared with diagnostic interviews. Although self-report screening measures, including the BDI, have been validated against well-established psychiatric methods in dialysis patients [8, 10, 40], the most accurate way of screening for depression (without professional evaluation) remains largely unresolved [1, 2, 28], and is predominantly influenced by the issue of criterion contamination. Watnick et al. [10] used the Structured Clinical Interview for Depression (DSM-IV), and reported that 19% of dialysis patients satisfied the DSM-IV [41] criteria for depression. Whilst the type of diagnostic or screening criteria employed may contribute to the varied level of reported prevalence [28, 42], there are also issues relating to statistical power. In a classic comparative study of dialysis patients, Smith et al. [28], using the BDI, demonstrated that 47% of patients satisfied the cut-off for depression, compared to 17% using the Multiple Affect Adjective Checklist and only 5% via a professional psychiatric evaluation. Contention still remains regarding the preferred depression screening tool/technique for the dialysis population. Using an existing or modified depression tool (BDI for example) for the dialysis population is viable. A more ideal, yet problematic, task would be to develop a specific depression assessment tool for the dialysis population. Currently, this work is unlikely to succeed until we improve our understanding of the issues surrounding depression assessment in patients with a chronic illness.

Mortality and Depression among the Dialysis Population

Mortality related to major depression among the general population has been highlighted empirically in several studies [43], despite some methodological issues. Research has shown that depression increases the risk of mortality, particularly via cardiovascular disease [43]. This association has an obvious severe implication for patients with ESRD, as cardiovascular disease remains the largest cause of death among this patient population [44]. The psychological and somatic effects of depression can complicate chronic illness [1, 2], reduce quality of life [37, 45, 46], reduce the motivation to maintain self-care and increase hospitalization rates [34]. The association

between depression and immune function is well recognized [47–49]. In ESRD, significant associations have been reported between depression, immune parameters and mortality [45], although some of the data is limited and conflicting [50]. Immune dysfunction may impact upon infection, which is the second largest cause of death among the ESRD population [51]. Furthermore, research has shown significant associations between depression and nutritional status, which could mediate the relationship between depression and mortality in this population [45, 52].

The association between depression and mortality, in both HD and PD, has been demonstrated in several studies [1, 2, 21, 34, 53–57]. Einwohner et al. [55] administered the Zung Depression Scale to a sample of PD patients, and reported that depression independently predicted patient mortality after controlling for serum albumin and comorbidity. Shulman et al. [58] investigated the 2-year survival of HD patients, and found those who had a BDI score of < 14 had an 85% survival rate, whilst for those who scored > 25 the survival rate was 25% [58]. In a recent study, depression in HD patients predicted mortality after controlling clinical and sociodemographic variables [22]. The Dialysis Outcomes and Practice Patterns Study, a large international cohort study of dialysis patients, demonstrated that depression was independently related to mortality and hospitalization [34], albeit utilizing an unconventional depression screening tool [42]. Kimmel et al. [21] adopted a more conventional approach, administering the BDI and CDI to HD patients at 6-month intervals (mean number of assessments = 2.9 ± 1.7). Using time-varying covariate analysis, they found that both the BDI and CDI predicted mortality, with relative risks of 1.24 and 1.18, respectively. Other studies support an association between the CDI and mortality among dialysis patients [59]. However, several authors have failed to find an association between depression and mortality in dialysis patients [60–62], suggesting the need for further study. These reported variations may implicate differences in study designs, screening tools employed, populations studied and statistical methods used. In a recent longitudinal study of dialysis patients (HD and PD), Boulware et al. [33] investigated the relationship between depressive symptoms, cardiovascular events and mortality. Time-varying models demonstrated that the symptoms of depression were associated with increased all-cause mortality, cardiovascular disease mortality and cardiovascular events, whereas baseline measures were not. However, the significance of these associations was reduced after deploying a 6-month time lag in the analy-

sis. This implies a role for comorbidity in the genesis of depression, rather than depression leading to increased morbidity. This example of reverse causality may help explain some of the previously reported variation [3].

Suicide contributes to the mortality rate associated with major depression. The lifetime suicide risk associated with major depression is estimated to be around 3.4% [63]. Among the dialysis population suicide accounts for around 0.2 deaths per 1,000 patient-years [42, 64]. A recent study of suicide among the United States ESRD programme revealed the standardized incidence ratio of suicide to be 1.84 (95% CI 1.5–2.27). This equates to an 84% higher suicide risk compared with the general population [64]. Approximately 20% of ESRD patients choose to withdraw from dialysis treatment [1, 65, 66], and this is associated with multiple factors including chronic medical comorbidity [67, 68], age [69], ethnicity and gender [67]. The influence of depression upon the decision to withdraw from dialysis treatment has received little attention. A recent study showed that depression was a significant risk factor for withdrawal from HD, even after controlling for age and other clinical variables [71]. Ganzini et al. [72] proposed that patients with major depression should not be encouraged to make a decision about withdrawal until after a period of antidepressant treatment. Whether withdrawal is independently influenced by depression is a complex and controversial issue. Cohen et al. [73] proposed that other neuropsychiatric disorders such as dementia were more relevant than depression in influencing withdrawal decisions. The association between depression and withdrawal from dialysis requires further study. Around 20% of ESRD patients suffer from depression [1, 8, 29, 74], whilst a similar proportion choose to withdraw from dialysis [1, 65, 66]. Researchers need to define the degree of overlap.

Treatment Modality and Depression

Successful transplantation is associated with reduced levels of anxiety and depression compared with those experienced by dialysis patients [75, 76]. The impact of the dialysis modality on the prevalence of depression has yielded contradictory findings [32, 77, 78] and has not been extensively explored. It has been suggested that the prevalence and severity of depression was significantly lower in patients receiving PD compared with those on HD [37]. Feelings of control (health locus of control) may provide a partial explanation for such differences. Wuerth et al. [79] studied the modality choice of PD patients and

reported the main reason for choosing PD was that it offered more autonomy and control. Other significant factors included the preference to undertake dialysis at home and the increased flexibility of dialysis schedule afforded by PD [79]. In another study, 85% of PD patients rated their care as excellent compared to 56% of HD patients [80]. The perceived feelings of control and social support may be influenced by the characteristics of a particular dialysis modality. These differences and their relationship to the prevalence of depression merit further study.

Causes of Depression

The aetiology of depression among general and chronically ill populations is multifactorial relating to social, psychological and biological mechanisms. The high prevalence of depression among the chronically ill reflects significant and prolonged changes to the social environment, psychological state, physical ability and pathology. The multiple stressors associated with ESRD may have profound effects on depressive symptomatology. Hopelessness and distress are prominent features of depression among dialysis patients [81]. The routine of dialysis treatment and varying levels of health may impact upon feelings of hopelessness, which may induce episodes of depression. Applying a psychodynamic model to ESRD links depression with the perception of loss [2, 9, 13]. Patients with ESRD encounter losses on both a somatic and psychological level. The dependency upon treatment, accompanied by numerous losses, may lead to perceived feelings of a lack of control [4–7]. Martin and Thompson [82] showed that locus of control measures were significant predictors of work status, cognitive function and physical function. Others have found that mechanisms of internal control are associated with reduced depression among renal dialysis patients [83]. Cvengros et al. [84] studied health locus of control and depression in patients with chronic kidney disease progressing to ESRD. The results revealed that as the disease progressed to requiring dialysis, changes in internal control predicted depression. Interestingly, the relationship was maintained when the somatic elements of the depression assessment (BDI) were removed, thus avoiding the overlap between somatic depression scoring and disease progression [84]. Such empirical evidence supports cognitive adaptation theory [85] which proposes that when faced with psychological adversity (i.e. reaction to illness) perceptions of personal control are heightened, promoting feelings of mastery. Increased feelings of control may elicit improved coping

responses and in turn better adjustment. Furthermore, the invasive routine of dialysis, and associated stress, may inhibit the use of certain coping strategies [86, 37]. The association between illness control and depression has also been shown to depend upon contextual factors, such as a kidney transplant failure [83]. Christensen et al. [83] revealed that heightened internal control was associated with increased depression in patients who had experienced a failed kidney transplant, whereas in those with no transplant history, increased control was associated with reduced depression.

Alternative explanations view depression as the direct or indirect consequence of the renal failure. For example, there are increased levels of cytokines and acute-phase reactants in patients with ESRD [50], possibly implicating cytokine-induced depression [1, 88–90] in the pathogenesis of depression in dialysis patients. Israel [13] reported that uraemia itself may cause depression and suggested a possible genetic predisposition within the ESRD population [13]. Uraemia may impact upon the central nervous system, affecting the synthesis and metabolism of certain neurotransmitters [91]. Increasing evidence has supported the benefits of daily HD upon uraemic symptomatology [92–95], although there is limited evidence to suggest that daily dialysis is associated with a reduction in depression. Two recent abstracts have reported improvements in patients' BDI scores after converting to frequent HD (short daily, or nocturnal HD) [96, 97]. Although anecdotal, this suggests that more effective control of uraemia impacts upon depression and mood. However, there is a great need to test such assertions in controlled studies.

Treatment

Comorbid depression among the medically ill may be different from that of psychiatric illness [2, 13, 40] and harder to treat [98]. Conventional guidelines (NICE) on depression treatment in primary and secondary care may be complicated when applied to the ESRD population, particularly recognition and pharmacological treatment. For example, a widely used class of antidepressants, selective serotonin reuptake inhibitors (SSRI), block cytochrome P450 and thereby increase significant drug-drug interactions, which may be a problem for dialysis patients on a stringent list of medication [99]. The high protein-binding properties of certain antidepressants may cause renal dialysis patients to be more responsive to psychotropic interventions [8]. For a range of antidepressants,

including SSRI and serotonin norepinephrine reuptake inhibitors, a cautious approach to prescription is advised, starting with a low dose increasing over time [56]. A group of antidepressants, including citalopram and paroxetine (SSRI), along with initial and usual dosage guidelines have been suggested [100, 101; for a review, see 102]. Tricyclic antidepressants are often avoided due to an increased risk of cardiac problems [103]. Fluoxetine (20 mg/day), in a double-blind placebo-controlled study of HD patients, was found to be effective in alleviating depression symptoms with no significant side effects [104]. While the effective use of antidepressants among dialysis patients has been demonstrated in a small number of studies [56], further research is required to determine the impact of such treatment upon patient outcome and mortality [2].

Due to the difficulties of using drugs in these situations, psychological interventions may be a suitable alternative [105], though the evidence base is sparse. The evidence available suggests that cognitive behavioural therapy may be effective in relieving depression in the dialysis population [106, 107], as may other novel psychological interventions [108].

Wuerth et al. [29] have raised a more fundamental issue regarding treating depression in this population. Many patients refuse evaluation, and few complete the desired course of antidepressant treatment. This may be due to an underlying stigma of depression, which could perhaps be resolved by increased education. Educating staff and patients may promote earlier detection and treatment [109]. Employing a more holistic approach may be the most effective form of treatment for dialysis patients [110].

More effective dialysis may have a role. Daily HD was shown to improve quality of life [93, 94, 111], although these studies were small and largely uncontrolled. There are also significant potential downsides. While daily dialysis may be more effective in controlling uraemia, for some, the daily impact of dialysis and increased treatment-related stress may amplify the burden of treatment [112].

Conclusions

Depression is a prevalent and costly burden to dialysis patients impacting on a psychological and somatic level. Under-recognition of depression in this population is a major concern, particularly given the evidence of its impact on comorbidity and mortality. Longitudinal re-

search is needed to clarify the causal antecedents of depression among patients, the predictive risk factors, its prevalence, its relation to modality and its influence on the decision to withdraw from treatment. The issues regarding criterion contamination require specific attention, since this has a bearing on depression screening across a range of medical conditions. There is a need to establish the correct tools and procedures for depression

screening among dialysis patients. Treating depressed dialysis patients has received little attention, particularly with respect to psychological interventions. However, regardless of the treatment options available, many patients refuse evaluation and treatment. Modifying patient and staff education may help improve this process. This catalogue of needs underlines our current state of ignorance.

References

- 1 Kimmel PL: Psychosocial factors in dialysis patients. *Kidney Int* 2001;59:1599–1613.
- 2 Kimmel PL, Weihs K, Peterson RA: Survival in hemodialysis patients: the role of depression. *J Am Soc Nephrol* 1993;4:12–27.
- 3 Kimmel PL: Depression in patients with chronic renal disease: what we know and what we need to know. *J Psychosom Res* 2002;53:951–956.
- 4 De-Nour AK, Shaltiel J, Czaczkes JW: Emotional reactions of patients on chronic hemodialysis. *Psychosom Med* 1968;30:521–533.
- 5 O'Brien ME: Compliance behavior and long-term maintenance dialysis. *Am J Kidney Dis* 1990;15:209–214.
- 6 Reiss D: Patient, family, and staff responses to end-stage renal disease. *Am J Kidney Dis* 1990;15:194–200.
- 7 De-Nour AK: Social adjustment of chronic dialysis patients. *Am J Psychiatry* 1982;139:97–100.
- 8 Finkelstein FO, Finkelstein SH: Depression in chronic dialysis patients: assessment and treatment. *Nephrol Dial Transplant* 2000;15:1911–1913.
- 9 Levenson JL, Glocheski S: Psychological factors affecting end-stage renal disease: a review. *Psychosomatics* 1991;32:382–389.
- 10 Watnick S, Wang PL, Demadura T, Ganzini L: Validation of 2 depression screening tools in dialysis patients. *Am J Kidney Dis* 2005;46:919–924.
- 11 Killingworth A, van den Akker O: The quality of life of renal dialysis patients: trying to find the missing measurement. *Int J Nurs Stud* 1996;33:107–120.
- 12 Stein MB, Cox BJ, Afifi TO, Belik SL, Sareen J: Does co-morbid depressive illness magnify the impact of chronic physical illness? A population-based perspective. *Psychol Med* 2006;36:587–596.
- 13 Israel M: Depression in dialysis patients: a review of psychological factors. *Can J Psychiatry* 1986;31:445–451.
- 14 Cummings JL: Depression and Parkinson's disease: a review. *Am J Psychiatry* 1992;149:443–454.
- 15 Schwab JJ, Bialow M, Brown JM, Holzer CE: Diagnosing depression in medical inpatients. *Ann Intern Med* 1967;67:695–707.
- 16 Klein D, Gittelman R, Quitkin F, et al: *Diagnosis and Drug Treatment of Psychiatric Disorders: Adults and Children*, ed 2. Baltimore, Lippincott Williams & Wilkins, 1980.
- 17 Koenig HG, George LK, Peterson BL, Pieper CF: Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. *Am J Psychiatry* 1997;154:1376–1383.
- 18 Cavanaugh S, Clark DC, Gibbons RD: Diagnosing depression in the hospitalized medically ill. *Psychosomatics* 1983;24:809–815.
- 19 Craven JL, Rodin GM, Johnson L, Kennedy SH: The diagnosis of major depression in renal dialysis patients. *Psychosom Med* 1987;49:482–492.
- 20 Sacks CR, Peterson RA, Kimmel PL: Perception of illness and depression in chronic renal disease. *Am J Kidney Dis* 1990;15:31–39.
- 21 Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Cruz I, Veis JH: Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. *Kidney Int* 2000;57:2093–2098.
- 22 Drayer RA, Piraino B, Reynolds CF III, Houck PR, Mazumdar S, Bernardini J, Shear MK, Rollman BL: Characteristics of depression in hemodialysis patients: symptoms, quality of life and mortality risk. *Gen Hosp Psychiatry* 2006;28:306–312.
- 23 Drayer RA, Mulsant BH, Lenze EJ, Rollman BL, Dew MA, Kelleher K, Karp JF, Begley A, Schulberg HC, Reynolds CF III: Somatic symptoms of depression in elderly patients with medical comorbidities. *Int J Geriatr Psychiatry* 2005;20:973–982.
- 24 Chilcot J, Wellsted DM, Farrington K: Screening for depression while patients dialyze. *Nephrology Dialysis Transplantation* 2008, in press.
- 25 Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA* 2003;289:3095–3105.
- 26 Steptoe A: *Depression and Physical Illness*. Cambridge, Cambridge University Press, 2006.
- 27 Lowry MR, Atcherson E: A short-term follow-up of patients with depressive disorder on entry into home dialysis training. *J Affect Disord* 1980;2:219–227.
- 28 Smith MD, Hong BA, Robson AM: Diagnosis of depression in patients with end-stage renal disease: comparative analysis. *Am J Med* 1985;79:160–166.
- 29 Wuerth D, Finkelstein SH, Ciarcia J, Peterson R, Kliger AS, Finkelstein FO: Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. *Am J Kidney Dis* 2001;37:1011–1017.
- 30 Wilson B, Spittal J, Heidenheim P, Herman M, Leonard M, Johnston A, Lindsay R, Moist L: Screening for depression in chronic hemodialysis patients: comparison of the Beck Depression Inventory, primary nurse, and nephrology team. *Hemodial Int* 2006;10:35–41.
- 31 Lopes AA, Albert JM, Young EW, Satayathum S, Pisoni RL, Andreucci VE, Mapes DL, Mason NA, Fukuhara S, Wikstrom B, Saito A, Port FK: Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. *Kidney Int* 2004;66:2047–2053.
- 32 Martin CR, Tweed AE, Metcalfe MS: A psychometric evaluation of the Hospital Anxiety and Depression Scale in patients diagnosed with end-stage renal disease. *Br J Clin Psychol* 2004;43:51–64.
- 33 Boulware LE, Liu Y, Fink NE, Coresh J, Ford DE, Klag MJ, Powe NR: Temporal relation among depression symptoms, cardiovascular disease events, and mortality in end-stage renal disease: contribution of reverse causality. *Clin J Am Soc Nephrol* 2006;1:496–504.
- 34 Lopes AA, Bragg J, Young E, Goodkin D, Mapes D, Combe C, Piera L, Held P, Gillespie B, Port FK: Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. *Kidney Int* 2002;62:199–207.

- 35 Hinrichsen GA, Lieberman JA, Pollack S, Steinberg H: Depression in hemodialysis patients. *Psychosomatics* 1989;30:284–289.
- 36 Hedayati SS, Bosworth HB, Kuchibhatla M, Kimmel PL, Szczech LA: The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. *Kidney Int* 2006;69:1662–1668.
- 37 Kalender B, Ozdemir AC, Dervisoglu E, Ozdemir O: Quality of life in chronic kidney disease: effects of treatment modality, depression, malnutrition and inflammation. *Int J Clin Pract* 2007;61:569–576.
- 38 Kim JA, Lee YK, Huh WS, Kim YG, Kim DJ, Oh HY, Kang SA, Kim Moon YH, Kim HW, Kim JH: Analysis of depression in continuous ambulatory peritoneal dialysis patients. *J Korean Med Sci* 2002;17:790–794.
- 39 Martucci M, Balestrieri M, Bisoffi G, Bonizzato P, Covre MG, Cunico L, De Francoso M, Marinoni MG, Mosciaro C, Piccinelli M, Vaccari L, Tansella M: Evaluating psychiatric morbidity in a general hospital: a two-phase epidemiological survey. *Psychol Med* 1999;29:823–832.
- 40 Craven JL, Rodin GM, Littlefield C: The Beck Depression Inventory as a screening device for major depression in renal dialysis patients. *Int J Psychiatry Med* 1988;18:365–374.
- 41 American Psychiatric Association: *Diagnostic and Statistical Manual of Mental Disorders*, ed 4. Washington, American Psychiatric Association, 1994.
- 42 Kimmel PL, Peterson RA: Depression in end-stage renal disease patients treated with hemodialysis: tools, correlates, outcomes, and needs. *Semin Dial* 2005;18:91–97.
- 43 Wulsin LR, Vaillant GE, Wells VE: A systematic review of the mortality of depression. *Psychosom Med* 1999;61:6–17.
- 44 Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 1998;32:S112–S119.
- 45 Koo JR, Yoon JW, Kim SG, Lee YK, Oh KH, Kim GH, Kim HJ, Chae DW, Noh JW, Lee SK, Son BK: Association of depression with malnutrition in chronic hemodialysis patients. *Am J Kidney Dis* 2003;41:1037–1042.
- 46 Knight EL, Ofsthun N, Teng M, Lazarus JM, Curhan GC: The association between mental health, physical function, and hemodialysis mortality. *Kidney Int* 2003;63:1843–1851.
- 47 Irwin M: Immune correlates of depression. *Adv Exp Med Biol* 1999;461:1–24.
- 48 Maes M, Vandoolaeghe E, Ranjan R, Bosmans E, Bergmans R, Desnyder R: Increased serum interleukin-1-receptor-antagonist concentrations in major depression. *J Affect Disord* 1995;36:29–36.
- 49 Appels A, Bar FW, Bar J, Bruggeman C, de Baets M: Inflammation, depressive symptomatology, and coronary artery disease. *Psychosom Med* 2000;62:601–605.
- 50 Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yarovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. *Kidney Int* 1998;54:236–244.
- 51 USRDS: Excerpts from United States Renal Data System 1991 annual data report. *Am J Kidney Dis* 1991;18:1–127.
- 52 Bilgic A, Akgul A, Sezer S, Arat Z, Ozdemir FN, Haberal M: Nutritional status and depression, sleep disorder, and quality of life in hemodialysis patients. *J Ren Nutr* 2007;17:381–388.
- 53 Juergensen PH, Wuertth DB, Juergensen DM, Finkelstein SH, Steele TE, Kliger AS, Finkelstein FO: Psychosocial factors and clinical outcome on CAPD. *Adv Perit Dial* 1997;13:121–124.
- 54 Troidle L, Watnick S, Wuertth DB, Gorbann-Brennan N, Kliger AS, Finkelstein FO: Depression and its association with peritonitis in long-term peritoneal dialysis patients. *Am J Kidney Dis* 2003;42:350–354.
- 55 Einwohner R, Bernardini J, Fried L, Piraino B: The effect of depressive symptoms on survival in peritoneal dialysis patients. *Perit Dial Int* 2004;24:256–263.
- 56 Kennedy SH, Craven JL, Rodin GM: Major depression in renal dialysis patients: an open trial of antidepressant therapy. *J Clin Psychiatry* 1989;50:60–63.
- 57 Streltzer J: Diagnostic and treatment considerations in depressed dialysis patients. *Clin Exp Dial Apheresis* 1983;7:257–274.
- 58 Shulman R, Price JD, Spinelli J: Biopsychosocial aspects of long-term survival on end-stage renal failure therapy. *Psychol Med* 1989;19:945–954.
- 59 Peterson RA, Kimmel PL, Sacks CR, Mesquita ML, Simmens SJ, Reiss D: Depression, perception of illness and mortality in patients with end-stage renal disease. *Int J Psychiatry Med* 1991;21:343–354.
- 60 Husebye DG, Westlie L, Styrvoky TJ, Kjellstrand CM: Psychological, social, and somatic prognostic indicators in old patients undergoing long-term dialysis. *Arch Intern Med* 1987;147:1921–1924.
- 61 Devins GM, Mann J, Mandin H, Paul LC, Hons RB, Burgess ED, Taub K, Schorr S, Letourneau PK, Buckle S: Psychosocial predictors of survival in end-stage renal disease. *J Nerv Ment Dis* 1990;178:127–133.
- 62 Christensen AJ, Wiebe JS, Smith TW, Turner CW: Predictors of survival among hemodialysis patients: effect of perceived family support. *Health Psychol* 1994;13:521–525.
- 63 Blair-West GW, Cantor CH, Mellsop GW, Eyeson-Annan ML: Lifetime suicide risk in major depression: sex and age determinants. *J Affect Disord* 1999;55:171–178.
- 64 Kurella M, Kimmel PL, Young BS, Chertow GM: Suicide in the United States end-stage renal disease program. *J Am Soc Nephrol* 2005;16:774–781.
- 65 USRDS: USRDS: the United States Renal Data System. *Am J Kidney Dis* 2003;42:1–230.
- 66 Cohen LM, Germain MJ, Poppel DM: Practical considerations in dialysis withdrawal: 'to have that option is a blessing'. *JAMA* 2003;289:2113–2119.
- 67 Bajwa K, Szabo E, Kjellstrand CM: A prospective study of risk factors and decision making in discontinuation of dialysis. *Arch Intern Med* 1996;156:2571–2577.
- 68 Mailloux LU, Bellucci AG, Napolitano B, Mossey RT, Wilkes BM, Bluestone PA: Death by withdrawal from dialysis: a 20-year clinical experience. *J Am Soc Nephrol* 1993;3:1631–1637.
- 69 Port FK, Wolfe RA, Hawthorne VM, Ferguson CW: Discontinuation of dialysis therapy as a cause of death. *Am J Nephrol* 1989;9:145–149.
- 70 Leggat JE Jr, Bloembergen WE, Levine G, Hulbert-Shearon TE, Port FK: An analysis of risk factors for withdrawal from dialysis before death. *J Am Soc Nephrol* 1997;8:1755–1763.
- 71 McDale-Montez EA, Christensen AJ, Cvenegros JA, Lawton WJ: The role of depression symptoms in dialysis withdrawal. *Health Psychol* 2006;25:198–204.
- 72 Ganzini L, Lee MA, Heintz RT, Bloom JD, Fenn DS: The effect of depression treatment on elderly patients' preferences for life-sustaining medical therapy. *Am J Psychiatry* 1994;151:1631–1636.
- 73 Cohen LM, Germain MJ, Tessier EG: Neuropsychiatric complications and psychopharmacology of end-stage renal disease; in Brady HR, Wilcox CS (eds): *Therapy of Nephrology and Hypertension: A Companion to Brenner's the Kidney*. Philadelphia, Elsevier Science, 2003, pp 731–746.
- 74 Watnick S, Kirwin P, Mahnensmith R, Concato J: The prevalence and treatment of depression among patients starting dialysis. *Am J Kidney Dis* 2003;41:105–110.
- 75 Cameron JI, Whiteside C, Katz J, Devins GM: Differences in quality of life across renal replacement therapies: a meta-analytic comparison. *Am J Kidney Dis* 2000;35:629–637.
- 76 Gudex CM: Health-related quality of life in endstage renal failure. *Qual Life Res* 1995;4:359–366.
- 77 Zimmermann PR, Poli de Figueiredo CE, Fonseca NA: Depression, anxiety and adjustment in renal replacement therapy: a quality of life assessment. *Clin Nephrol* 2001;56:387–390.
- 78 Devins GM, Binik YM, Hutchinson TA, Holmby DJ, Barre PE, Guttman RD: The emotional impact of end-stage renal disease: importance of patients' perception of intrusiveness and control. *Int J Psychiatry Med* 1983;13:327–343.
- 79 Wuertth DB, Finkelstein SH, Schwetz O, Carey H, Kliger AS, Finkelstein FO: Patients' descriptions of specific factors leading to modality selection of chronic peritoneal dialysis or hemodialysis. *Perit Dial Int* 2002;22:184–190.

- 80 Rubin HR, Fink NE, Plantinga LC, Sadler JH, Klinger AS, Powe NR: Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis. *JAMA* 2004;291:697-703.
- 81 Kim JA, Lee YK, Huh WS, Kim YG, Kim DJ, Oh HY, Kang SA, Kim Moon YH, Kim HW, Kim JH: Analysis of depression in continuous ambulatory peritoneal dialysis patients. *J Korean Med Sci* 2002;17:790-794.
- 82 Martin CR, Thompson DR: Prediction of quality of life in patients with end-stage renal disease. *Br J Health Psychol* 2000;5:41-55.
- 83 Christensen AJ, Turner CW, Smith TW, Holman JM Jr, Gregory MC: Health locus of control and depression in end-stage renal disease. *J Consult Clin Psychol* 1991;59:419-424.
- 84 Cvangros JA, Christensen AJ, Lawton WJ: Health locus of control and depression in chronic kidney disease: a dynamic perspective. *J Health Psychol* 2005;10:677-686.
- 85 Taylor SE: Adjustment to threatening events: a theory of cognitive adaptation. *Am Psychol* 1983;38:1161-1173.
- 86 Levy NB: Psychological complications of dialysis: psychonephrology to the rescue. *Bull Menninger Clin* 1984;48:237-250.
- 87 Devins GM, Binik YM, Mandin H, Burgess ED, Taub K, Letourneau PK, Buckle S, Low GL: Denial as a defense against depression in end-stage renal disease: an empirical test. *Int J Psychiatry Med* 1986;16:151-162.
- 88 Capuron L, Ravaut A, Miller AH, Dantzer R: Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. *Brain Behav Immun* 2004;18:205-213.
- 89 Wichers M, Maes M: The psychoneuroimmunopathophysiology of cytokine-induced depression in humans. *Int J Neuropsychopharmacol* 2002;5:375-388.
- 90 Kimmel PL, Peterson RA, Weihs KL, Shidler N, Simmens SJ, Alleyne S, Cruz I, Yanovski JA, Veis JH, Phillips TM: Dyadic relationship conflict, gender, and mortality in urban hemodialysis patients. *J Am Soc Nephrol* 2000;11:1518-1525.
- 91 Smogorzewski M, Ni Z, Massry SG: Function and metabolism of brain synaptosomes in chronic renal failure. *Artif Organs* 1995;19:795-800.
- 92 Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S: Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. *Am J Kidney Dis* 2003;42:1020-1035.
- 93 Kooistra MP, Vos J, Koomans HA, Vos PF: Daily home haemodialysis in the Netherlands: effects on metabolic control, haemodynamics, and quality of life. *Nephrol Dial Transplant* 1998;13:2853-2860.
- 94 Heidenheim AP, Muirhead N, Moist L, Lindsay RM: Patient quality of life on quotidian hemodialysis. *Am J Kidney Dis* 2003;42:36-41.
- 95 Andre MB, Rembold SM, Pereira CM, Lugo JR: Prospective evaluation of an in-center daily hemodialysis program: results of two years of treatment. *Am J Nephrol* 2002;22:473-479.
- 96 Brissenden J, Pierratos A, Ouwendyk M, Roscoe J: Improvements in quality of life with nocturnal hemodialysis (abstract). *J Am Soc Nephrol* 1998;9:168A.
- 97 Reynolds JT, Harding P, Wuerth D, Finkelstein S, Simon DB, Finkelstein FO: A one year prospective trial of short daily hemodialysis: quality of life (abstract). *J Am Soc Nephrol* 2001;13:410A.
- 98 Keitner GI, Ryan CE, Miller IW, Kohn R, Epstein NB: 12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). *Am J Psychiatry* 1991;148:345-350.
- 99 AHFS: AHFS drug information 2000. Bethesda, American Society of Health-System Pharmacists, 2000.
- 100 Whooley MA, Simon GE: Managing depression in medical outpatients. *N Engl J Med* 2000;343:1942-1950.
- 101 Lapid MI, Rummans TA: Evaluation and management of geriatric depression in primary care. *Mayo Clin Proc* 2003;78:1423-1429.
- 102 Wuerth D, Finkelstein SH, Finkelstein FO: The identification and treatment of depression in patients maintained on dialysis. *Semin Dial* 2005;18:142-146.
- 103 Cohen HW, Gibson G, Alderman MH: Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. *Am J Med* 2000;108:2-8.
- 104 Levy NB, Blumenfeld M, Beasley CM Jr, Dubey AK, Solomon RJ, Todd R, Goodman A, Bergstrom RR: Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. *Gen Hosp Psychiatry* 1996;18:8-13.
- 105 Christensen AJ, Ehlers SL: Psychological factors in end-stage renal disease: an emerging context for behavioral medicine research. *J Consult Clin Psychol* 2002;70:712-724.
- 106 Hener T, Weisenberg M, Har-Even D: Supportive versus cognitive-behavioral intervention programs in achieving adjustment to home peritoneal kidney dialysis. *J Consult Clin Psychol* 1996;64:731-741.
- 107 Cukor D, Friedman S: Towards the psychosocial treatment of depressed patients on dialysis. *Internet J Nephrol* 2005, vol 2.
- 108 Leake R, Friend R, Wadhwa N: Improving adjustment to chronic illness through strategic self-presentation: an experimental study on a renal dialysis unit. *Health Psychol* 1999;18:54-62.
- 109 Finkelstein FO, Watnick S, Finkelstein SH, Wuerth D: The treatment of depression in patients maintained on dialysis. *J Psychosom Res* 2002;53:957-960.
- 110 Kimura H, Ozaki N: Diagnosis and treatment of depression in dialysis patients. *Ther Apher Dial* 2006;10:328-332.
- 111 Vos PF, Zilch O, Kooistra MP: Clinical outcome of daily dialysis. *Am J Kidney Dis* 2001;37:S99-S102.
- 112 Kurella M, Suri RS, Chertow GM: Frequent hemodialysis and psychosocial function. *Semin Dial* 2005;18:132-136.